Briefing Note: Hepatitis B & Hepatitis C. Summary:
|
|
- Robert Wood
- 8 years ago
- Views:
Transcription
1 Briefing Note: Hepatitis B & Hepatitis C Summary: In Canada, hepatitis B and hepatitis C infections remain serious public health concerns due to high prevalence rates, high health care expenditures and increasing demand for resources for education, prevention, surveillance, care and treatment. Since 2009, the Canadian Coalition of Organizations Responding to Hepatitis B and C ( The Coalition ) has asked federal, provincial and territorial governments to respond by 2012 to 6 National Asks, written and agreed upon in 2008 by a committee of Canadian organizations. Having reviewed the Report Card issued by the Coalition in 2011 to measure government response to the 6 National Asks, and in keeping with the Coalition s belief that it is critical for Canadian governments to adopt a fully- funded, coordinated and comprehensive national strategy for both hepatitis B and hepatitis C, the Coalition recommends that 3 priority areas be addressed as soon as possible by all levels of government with tangible measures at the policy, program and service delivery levels. These priority areas are: Quick Facts: 1. Increasing awareness and preventing hepatitis B & hepatitis C infections among atrisk populations. 2. Improving access to health care and drug coverage. 3. Supporting communities and groups through stable funding for prevention, education, care and support. - Hepatitis B and hepatitis C are life-threatening liver diseases caused by the hepatitis B virus (HBV) and the hepatitis C virus (HCV), affecting approximately 600,000 people in Canada, many of whom are unaware they are infected. 1 - The prevalence of chronic hepatitis B infection in Canada is estimated to range between 0.7% and 0.9%. 2 The prevalence of hepatitis C infection in Canada is estimated to range between 0.8% and 1% and is increasing over time. 3
2 - Both hepatitis B and hepatitis C are responsible for many cases of cirrhosis, decompensated liver disease and hepatocellular carcinoma, increasing the need for liver transplantation. 4 - Although there is no vaccine for hepatitis C, hepatitis B virus immunization is available for the prevention of hepatitis B infection. 5 - As for hepatitis B treatment, various medications such as pegylated inteferon-alpha-2a, entecavir, lamivudine, telbivudine and adefovir are available according to patient age, the level of viral replication, HbeAg status, inflammation, amino alanine transferase (ALT) levels and risks for cirrhosis and hepatocellular carcinoma (HCC). 6 - The current gold standard of treatment for hepatitis C infection is pegylated interferonα in combination with ribavirin. 7 Combined with interferon injections and ribavirin pills, the latest hepatitis C drugs (boceprevir and telaprevir) are dramatically more effective for people with genotype 1 hepatitis C. 8 Interferon-free, all-oral combinations are likely to follow within the next two to five years. 9 - Overall, hepatitis C costs the Canadian healthcare system about $500 million annually. This is expected to double to $1 billion by The overall societal costs of not treating infected individuals increase the economic burden of hepatitis B and hepatitis C on Canadian society, with disease progression and hospitalization being the largest cost component throughout the course of disease The prevalence of HCV-related sequelae is expected to rise, with the most notable increases for those requiring liver transplants. Priority Areas: Increasing awareness & preventing Hepatitis B & C infections among at-risk populations In Canada, the highest rates of hepatitis C virus infection are reported among people who inject drugs, mostly from sharing used drug-use paraphernalia; the prevalence rate of hepatitis C among people who use drugs is approximately 69%. 12 The reported prevalence rates of hepatitis C among inmates, men who have sex with men (MSM), street youth and the aboriginal population are 28%, 5%, 5% and 3%, respectively. 13 While the prevalence of hepatitis B infection varies depending on population subgroups within Canada, the reported cases of hepatitis B have been decreasing since the introduction of hepatitis B vaccination programs. 14 Individuals who are at increased risk of hepatitis B include MSM, HIV-positive people and recent immigrants. 15 It has been illustrated that it is beneficial to implement a universal hepatitis B virus immunization program in infants for maximized population-level protection and a national immunization registry for evaluation. 16 Many studies indicate that a variety of strategies such as needle distribution and recovery programs, outreach strategies, overdose prevention, methadone use for detoxification and maintenance therapy as well as supervised consumption
3 and injection sites are safe, inexpensive and effective at preventing transmission of hepatitis B and hepatitis C. 17 Furthermore, sterile ( safe ) prison tattooing programs have been shown to reduce transmissions of hepatitis C infections in federal institutions. 18 Improving access to health care and drug coverage Improved access to health care services in all communities, along with standardization in drug coverage can significantly enhance the quality of life among infected individuals and subsequently reduce health care costs associated with hepatitis B and hepatitis C, which are now both treatable diseases. It has been demonstrated that hepatitis C virus positivity is correlated with increased medical expenditures, and prevention programs to decrease vulnerabilities such as mental health and addiction, as well as hepatitis C treatment are necessary for mitigating medical costs and health outcomes. 19 Also, action directed to reduce stigma and discrimination associated with drug use and hepatitis B or hepatitis C infection is required to improve access to health care for infected individuals and those at increased risk of developing hepatitis B and/or hepatitis C. 20 Other areas where access to health care could be improved include monitoring and shortening the waiting time for specialists and creating a national organ donation procurement program. As for drug coverage, standardization in drug plans and approval processes across the country would result in more consistency in drug coverage and consequently resolve inequities between provinces and territories within Canada. Such standardization would also ensure more timely and coordinated drug approvals for different sub-populations, such as people co-infected with HIV. Supporting communities and groups through stable funding for prevention, education and support Despite the existence of the Hepatitis C Prevention, Support and Research Program launched by the Public Health Agency of Canada in 1999, 21 instability and delays of federal funding have affected the ability of community-based organizations to provide outreach programs (harm reduction and education programs), care and support, all of which are areas embedded in the Program s major long-term goals. Consequently, this lack of funding and human resources has made it difficult for local organizations to reach out to those individuals most at risk. Availability of funding at the provincial and territorial levels varies greatly region to region, resulting in inconsistent service delivery. Furthermore, there is no similar dedicated program to hepatitis B supported by the Public Health Agency of Canada. Recommendations: That the Canadian federal, provincial and territorial governments adopt measures to address the national viral hepatitis epidemic from a public health perspective.
4 Promote campaigns encouraging communities, including baby boomers and immigrants, to get tested for hepatitis B and hepatitis C. Develop a universal neonatal hepatitis B virus immunization program for maximized population-level protection and a national immunization registry for evaluation. Endorse and implement supportive measures that reduce harm for people at risk, especially those who inject drugs and federal inmates. Develop broad-based prevention programs to reduce vulnerabilities and programs to identify and treat hepatitis C virus-infected individuals who are unaware of their infection. Standardize drug plans and approval processes to eliminate inequities between provinces and territories across Canada. Promote the continuity and expansion of funding to community-based organizations to ensure adequate interventions regarding prevention, education, care and support for both hepatitis B and hepatitis C. References 1. Public Health Agency of Canada (PHAC). (2012). Hepatitis. Retrieved from 2. PHAC. Hepatitis B: Get the Facts Retrieved from 3. Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, PHAC (2010). Hepatitis C in Canada : Surveillance Report (pp. 1-42). 4. Ibid. 5. PHAC. (2012). Hepatitis. Retrieved from 6. PHAC. (2008). Brief Report : Hepatitis B Infection in Canada. 7. PHAC. (2009). Management and Treatment of Chronic hepatitis C. Retrieved from 8. Bacon, B. R., Gordon, S. C., Lawitz, E., et al. (2011). Boceprevir for previously treated chronic hepatitis C virus genotype 1 infection. The New England Journal of Medicine, 364(13), Sharma, P., & Lok, A. S. (2011). Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology, 141(6),
5 10. Joint Advisory Committee of the Health Canada/CIHR Research Initiative on Hepatitis C. Hepatitis C As A Roadmap For Integrated Communicable Disease Prevention And Control: A Strategy For The Renewal Of The Health Canada/Canadian Institutes Of Health Research (CIHR) Research Initiative On Hepatitis C. Ottawa: Krajden, M., Zagorski, B., Alvarez, M., et al. (2010). Health care costs associated with hepatitis C : A longitudinal cohort study. Canadian Journal of Gastroenterology, 24(12), Jacobson, I. M., McHutchison, J. G., Dusheiko, G., et al. (2011). Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine, 364(25), McHutchison, J. G., Manns, M. P., Muir, A. J., Terrault, N. A, et al. (2010). Telaprevir for previously treated chronic HCV infection. The New England Journal of Medicine, 362(14), Poordad, F., McCone, J., Bacon, B. R., et al. (2011). Boceprevir for Untreated Chronic HCV Genotype 1 Infection. The New England Journal of Medicine, 364(13), Zeuzem, S., Andreone, P., Pol, S., et al. (2011). Telaprevir for retreatment of HCV infection. The New England journal of medicine, 364(25), Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, PHAC (2010). Hepatitis C in Canada : Surveillance Report (pp. 1-42). 13. Ibid. 14. PHAC. (2008). Brief Report : Hepatitis B Infection in Canada. 15. Ibid. 16. Mackie, C. O., Buxton, J. a, Tadwalkar, S., & Patrick, D. M. (2009). Hepatitis B immunization strategies: timing is everything. CMAJ : Canadian Medical Association Journal - Journal de l Association medicale canadienne, 180(2), Canadian Nurses Association (CNA). (2011). Harm Reduction and Currently Illegal Drugs. 18. Bonnycastle, K. D. (2011). The Social Organisation of Penal Tattooing in Two Canadian Federal Male Prisons: Locating Sites of Risk for Empirically-Based Health Care Interventions. The Howard Journal of Criminal Justice, 50(1), Krajden, M., Zagorski, B., Alvarez, M. (2010). Health care costs associated with hepatitis C : A longitudinal cohort study. Canadian Journal of Gastroenterology, 24(12),
6 20. Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, PHAC (2010). Hepatitis C in Canada : Surveillance Report (pp. 1-42). 21. PHAC. (2011). Hepatitis C Prevention, Support & Research Program. Retrieved from
Hepatitis C Infections in Oregon September 2014
Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with
More informationRecommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationGUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF
NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR
More informationHow you can protect investments, reduce health inequalities and save lives in your borough
Reducing health inequalities in London by addressing hepatitis C Briefing for councillors: Reducing health inequalities in London by addressing hepatitis C How you can protect investments, reduce health
More informationHepatitis C Virus Infection in Massachusetts: A tale of two epidemics
Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Daniel Church, MPH Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals of presentation Provide an overview
More informationNational Health Burden of CLD in Italy
National Health Burden of CLD in Italy 11,000 deaths due to liver cirrhosis or HCC in 2006 Direct costs for the National Health System for treating CLD patients: 420 M / year for hospital care 164 M /
More informationHepatitis C Treatment For Injecting Drugs
UPDATED 15. 5. 2015 PERSPECTIVES ON DRUGS Hepatitis C treatment for injecting drug users Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common
More informationFederal Government Standing Committee on Health
Federal Government Standing Committee on Health Inquiry into Hepatitis C in Australia Professor Gregory Dore Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia Infectious
More informationHepatitis C Virus (HCV)
HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median
More informationIntroduction. Background
INFORMATION DRIVES SOUND ANALYSIS, INSIGHT PHARMACY BENEFIT ADVISORY Introduction According to the Centers for Disease Control and Prevention (CDC), the rate of new hepatitis C virus (HCV) infections in
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationHepatitis C. Screening, Diagnosis and Linkage to Care
Hepatitis C Screening, Diagnosis and Linkage to Care Diagnosis If your hepatitis C antibody test is reactive, a second test will be needed to diagnose and determine if you are currently infected. Screening
More informationStrategies to Improve the HCV Continuum of Care:
Strategies to Improve the HCV Continuum of Care: Best Practices in Testing, Linkage to Care & Treatment Ronald O. Valdiserri, M.D., M.P.H. Deputy Assistant Secretary for Health, Infectious Diseases June
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationEMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN
EMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN JUNE 2014 INTRODUCTION Approximately 3.2 million individuals in the United States are infected with chronic hepatitis
More informationLiver Disease in Canada A CRISIS IN THE MAKING
Liver Disease in Canada A CRISIS IN THE MAKING AN ASSESSMENT OF LIVER DISEASE IN CANADA MARCH 2013 TABLE OF CONTENTS EXECUTIVE SUMMARY 2 INTRODUCTION 6 METHODS 6 LIVER DISEASES 6 CHAPTER 1 7 Hepatitis
More informationAlcohol and drugs prevention, treatment and recovery: why invest?
Alcohol and drugs prevention, treatment and recovery: why invest? 1 Alcohol problems are widespread 9 million adults drink at levels that increase the risk of harm to their health 1.6 million adults show
More informationNewly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide
Newly Diagnosed: HEPATITIS C American Liver Foundation Support Guide T he American Liver Foundation's mission is to facilitate, advocate, and promote education, support, and research for the prevention,
More informationHepatitis C treatment update
Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationThe Hepatitis B virus (HBV)
The Hepatitis B virus (HBV) There are 400 million people in the world who live with chronic hepatitis B, including France. Most people don t even know they are infected. But there are several important
More informationPlacing Nation on the Path Toward the Elimination of Hepatitis C
Placing Nation on the Path Toward the Elimination of Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for
More informationHepatitis C Treatment Advocacy: Ireland. Brian O Mahony
Hepatitis C Treatment Advocacy: Ireland Brian O Mahony Haemophilia and Hepatitis C 775 people with Haemophilia in Ireland 252 people with Haemophilia infected with Hepatitis C before 1992 106 of these
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationPoor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board
Poor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board The growing crisis of HIV/HCV coinfection It is estimated that 4-5 million people living with HIV (PLHIV)
More informationTHE A, B, C S OF HEPATITIS. Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas 75075 (972) 867-0019
THE A, B, C S OF HEPATITIS Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas 75075 (972) 867-0019 WHAT IS HEPATITIS? Hepatitis means inflammation of the liver
More information3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300.
April 3, 2014 3.6 million persons ever infected; 2.7 million chronic infections 1 Up to 75% unaware of status Transmitted through percutaneous exposure to infected blood Injection drug use (IDU) is the
More informationRibavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C
Ribavirin/Pegylated Combination Therapy for People with Hepatitis C 1. Introduction 2. What the treatment does 3. When to take it 4. What is? 5. What is interferon? 6. What is pegylated interferon? 7.
More informationHIV-AIDS: The Public Health Agency of Canada (PHAC) Report
UNGASS Country Progress Report CANADA Government of Canada Report to the Secretary General of the United Nations on the United Nations General Assembly Special Session on HIV/AIDS Declaration of Commitment
More informationHepatitis C - genotype 2/3
Hepatitis C - genotype 2/3 Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other
More informationRecommendations for the Public Health Response to Hepatitis C in Ontario. Provincial Infectious Diseases Advisory Committee on Communicable Diseases
Recommendations for the Public Health Response to Hepatitis C in Ontario Provincial Infectious Diseases Advisory Committee on Communicable Diseases July 2014 Public Health Ontario Public Health Ontario
More informationHepatitis at a national level: government perspectives
Hepatitis at a national level: government perspectives Presenter: Dr Shin Young-Soo Regional Director WHO Western Pacific Panel The Honourable Dr. David Sergeenko Minister of Health, Labour and Social
More informationExamining Hepatitis C Treatment Access: What Nurses Need to Know
Examining Hepatitis C Treatment Access: What Nurses Need to Know Ryan Clary, Executive Director, National Viral Hepatitis Roundtable Robert Greenwald, Director, Center for Health Law and Policy Innovation;
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More informationPRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
More informationNew All Oral Therapy for Chronic Hepatitis C Virus (HCV): A Cost-Benefit Analysis
New All Oral Therapy for Chronic Hepatitis C Virus (HCV): A Cost-Benefit Analysis Jennifer Orsi, MPH 4 th International Conference on Viral Hepatitis March 17, 2014 2014 Walgreen Co. All rights reserved.
More informationGuidelines for Viral Hepatitis CTR Services
Guidelines for Viral Hepatitis CTR Services During the 2007 North Dakota Legislative Assembly, legislation that called for the creation of a viral hepatitis program was introduced and approved. The North
More information2015 Outpatient Chronic Hepatitis B Management
2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis
More informationTwenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones
Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones 3 Executive Summary 4 Introduction 5 The
More informationSCHEDULE 2 THE SERVICES. NHS England
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. Service Commissioner Lead F04 S f Operational Delivery Networks for Hepatitis C Care in Adults NHS England Provider Lead Period
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationNews Release. FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 (908) 740-1898
News Release FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 Investor Contact: Amy Klug (908) 740-1898 Merck Receives Approval of ZEPATIER (elbasvir/grazoprevir) in Canada for the Treatment
More informationBurden of hepatitis C in Europe the case of France and Romania
Burden of hepatitis C in Europe the case of France and Romania Presented to: European Liver Patients Association Version: Final version 2.3 Date: 2015-03-26 Table of contents 1. Executive summary... 5
More informationManagement of Chronic Hepatitis B: Consensus Guidelines
Management of Chronic Hepatitis B: Consensus Guidelines Morris Sherman MD PhD 1, Stephen Shafran MD 2, Kelly Burak MD 3, Karen Doucette MD 2, Winnie Wong MD 2, Nigel Girgrah MD 1, Eric Yoshida MD 4, Eberhard
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationAustralian Federation of AIDS Organisations (AFAO) Primary Health Care Reform
Australian Federation of AIDS Organisations (AFAO) Primary Health Care Reform 27 February 2009 1 Introduction The Australian Federation of AIDS Organisations (AFAO) is the peak body for Australia s community
More informationHARM REDUCTION FOR PEOPLE WHO INJECT DRUGS INFORMATION NOTE
HARM REDUCTION FOR PEOPLE WHO INJECT DRUGS INFORMATION NOTE Introduction The Global Fund supports evidence-based interventions that aim to ensure access to HIV prevention, treatment, care and support for
More informationHepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014
Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go
More informationAssessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C
Department of Veterans Affairs Health Services Research & Development Service Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C March 2013 Prepared for: Department of Veterans
More informationTESTING AND MANAGEMENT. Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL
TESTING AND MANAGEMENT Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL Disclosure and acknowledgments No conflicts of interest Board Member of Hepatitis
More informationLiver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to
Manifesto by the European Liver Patients Association (ELPA) on policy measures against chronic liver disease 2014 to 2019 Why this manifesto? Every five years European voters get the opportunity to have
More informationCOMBATING THE SILENT EPIDEMIC of VIRAL HEPATITIS
United States Department of Health & Human Services COMBATING THE SILENT EPIDEMIC of VIRAL HEPATITIS Action Plan for the Prevention, Care & Treatment of Viral Hepatitis U.S. Department of Health & Human
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationdrug treatment in england: the road to recovery
The use of illegal drugs in England is declining; people who need help to overcome drug dependency are getting it quicker; and more are completing their treatment and recovering drug treatment in ENGlaND:
More informationFindings from the Community HIV/HCV Evaluation and Reporting Tool (CHERT)
Findings from the Community HIV/HCV Evaluation and Reporting Tool (CHERT) PAN Fall Conference October 22, 2014 Presented by: Elayne Vlahaki, President, Catalyst Consulting Inc. evlahaki@catalystresearchgroup.com
More informationManagement of Chronic Hepatitis B: 2012 Update
Management of Chronic Hepatitis B: 2012 Update Brian J McMahon MD, Liver Disease and Hepatitis Program Alaska Native Medical Center and Arctic Investigations Program, CDC Conflicts of Interest The Liver
More informationUsing Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services
Using Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services ADP Training Conference, Sacramento, August 21, 2012 Rachel McLean, MPH, CA Dept. of Public
More informationCalifornia Adult Viral Hepatitis Prevention. Strategic Plan, 2010-2014
California Adult Viral Hepatitis Prevention Strategic Plan, 2010-2014 A Report of the California Adult Viral Hepatitis Prevention Coordinating Committee and State of California California Department of
More informationDrugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP
Drugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP Habit is habit, and not to be flung out of the window by any man, but coaxed down-stairs one step at a time. Samuel Langhorne Clemens
More informationPublic Health Plan for the Pharmaceutical Treatment of Hepatitis C
Public Health Plan for the Pharmaceutical Treatment of Hepatitis C December 2014 Contents 1. Introduction...2 2. The Scale of the Problem..4 2.1 Epidemiology of hepatitis C...4 2.2 Burden of disease.....7
More informationSeptember 17, 2010. Dear Secretary Sebelius:
September 17, 2010 Secretary Kathleen Sebelius Department of Health and Human Services Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201 RE: Comments on OCIIO- 9992- IFC, Interim
More informationHBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
More informationViral hepatitis. Report by the Secretariat
SIXTY-THIRD WORLD HEALTH ASSEMBLY A63/15 Provisional agenda item 11.12 25 March 2010 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses (hepatitis A, B, C, D and
More information12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS
HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should
More informationProvincially Funded Health and Social Services
Provincially Funded Health and Social Services Health and social services are funded in Ontario by the Ministry of Health and Long- Term Care, the Ministry of Community and Social Services and the Ministry
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationINFORMATION ABOUT HEPATITIS C
INFORMATION ABOUT HEPATITIS C PATIENT BOOKLET Index 1 About Hepatitis C About Hepatitis C Page 1 Hepatitis C Transmission Page 3 Hepatitis C Disease Progression Page 4 Hepatitis C Diagnosis and Treatment
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
More informationTHE DATA FOR ADULT DRUG TREATMENT LINCOLNSHIRE LINCOLNSHIRE E08B 32
THE DATA FOR ADULT DRUG TREATMENT LINCOLNSHIRE LINCOLNSHIRE E08B 32 THIS SUPPORTING INFORMATION This pack sets out the investment in drug in your area. It also gives key performance information about your
More informationChronic Viral Hepatitis and Health Care Reform
Chronic Viral Hepatitis and Health Care Reform The purpose of this report is to outline and describe the basic required elements of health care for persons with chronic viral hepatitis infections. BACKGROUND
More informationPreface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636)
Preface The purpose of this CDC Hepatitis C Counseling and Testing manual is to provide guidance for hepatitis C counseling and testing of individuals born during 1945 1965. The guide was used in draft
More informationPatients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Liver International ISSN 1478-3223 REVIEW ARTICLE Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Mitchell L. Shiffman 1 and Yves Benhamou 2 1 Liver Institute of Virginia, Bon Secours
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationPart 5: Harm Reduction
Part 5: Harm Reduction Introduction Harm reduction principles are foundational to public health and community based programming intended to meet the needs of injection drug users (1). Harm reduction: Is
More informationdrug dependence treatment and care
UNODC-WHO Joint Programme on drug dependence treatment and care The vision Effective and humane treatment for all people with drug use disorders. Nothing less than would be expected for any other disease.
More informationTake Action Against Hepatitis C For People in Recovery From Mental Illness or Addiction
Take Action Against Hepatitis C For People in Recovery From Mental Illness or Addiction Attention treatment providers in behavioral health programs! This booklet is intended for use with clients who: Are
More informationHepatitis B. What I need to know about. National Digestive Diseases Information Clearinghouse NATIONAL INSTITUTES OF HEALTH
What I need to know about Hepatitis B U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH National Digestive Diseases Information Clearinghouse What I need to know about Hepatitis
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationDE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
More informationIN THE SENATE OF THE UNITED STATES , 2003. M. introduced the following bill; which was referred to the Committee on A BILL
DRAFT //0 0TH CONGRESS ST SESS. S. To direct the Secretary of Health and Human Services to establish, promote, and support a comprehensive program for education, prevention, and treatment of Hepatitis
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More information2003 VERMONT VIRAL HEPATITIS PREVENTION AND CONTROL PLAN
2003 VERMONT VIRAL HEPATITIS PREVENTION AND CONTROL PLAN Data Revision - October 2006 The Vermont Viral Hepatitis Prevention and Control Plan was funded by a planning grant from the Council of State and
More informationPRACTICAL STEPS TO ELIMINATING HEPATITIS C: A CONSENSUS FOR LONDON
PRACTICAL STEPS TO ELIMINATING HEPATITIS C: A CONSENSUS FOR LONDON NOVEMBER 2014 The London Joint Working Group on Substance Use and Hepatitis C (LJWG) Dr Kosh Agarwal David Badcock Dr Ashley Brown Janet
More informationPURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.
COVENTRY Health Care Guidelines for Hepatitis B Therapy SUBJECT: Chronic Hepatitis B Therapy: a. Interferons - Intron A (interferon alfa-2b) and Pegasys (peginterferon alfa-2a) b. Nucleoside analogues
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationPL-P2 Hepatitis C Treatment Expansion
POLICY LEVEL PLP2 Hepatitis C Treatment Expansion RECOMMENDATION SUMMARY TEXT The Health Care Authority (HCA) requests $77,738,000 ($20,019,000 GFState) in the 2016 Supplemental to expand treatment for
More informationTreating Chronic Hepatitis C. A Review of the Research for Adults
Treating Chronic Hepatitis C A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have chronic hepatitis C.
More informationDr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor. Hepatology-2014
Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor Hepatology-2014 Other virus hepatitis Epstein-Barr vírus Cytomegalo vírus Herpes simplex vírus Coxsackie vírus Hepatitis B vírus Hepadnavírus,
More informationMarketVIEW: Hepatitis C Virus (HCV) vaccines (CAT: VAMV042) Background. ****Published February 2013***
****Published February 2013*** MarketVIEW: Hepatitis C Virus (HCV) vaccines (CAT: VAMV042) Product Name : MarketVIEW: Hepatitis C Virus (HCV) vaccines Description : Global vaccine commercial opportunity
More informationWhy invest? How drug treatment and recovery services work for individuals, communities and society
Why invest? How drug treatment and recovery services work for individuals, communities and society What is drug addiction? Drug addiction is a complex but treatable condition Those affected use drugs compulsively,
More information2013-14 Report on Plans and Priorities Additional Information for Sub-programs and Sub-sub-programs
2013-14 Report on Plans and Priorities Additional Information for Sub-programs and Sub-sub-programs Strategic Outcome: Protecting Canadians and empowering them to improve their health Program 1.1 Public
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More information1.How did I get Hepatitis C?
1.How did I get Hepatitis C? Sharing needles and syringes ( iv drug use ) or using contaminated straws to snort cocaine Reused needles or medications in a health care setting- (LV endoscopy outbreak, glucometers
More information